A Phase 1/2 interventional study of ABX196 in Carcinoma, Hepatocellular, sponsored by Abivax S.A.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Abivax S.A. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 630th largest by enrollment of the 775 interventional ones that give a count, is one of 35 that started in 2020, is one of 112 in phase 1/2, and was the 593rd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Varian, a Siemens Healthineers Company · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
926 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 336 · Phase 2 376 · Phase 3 66 · Phase 4 14
First in 1977; this study’s year is marked. 35 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 36 across the 775 interventional studies, 132 across the 121 observational. Of the 602 that completed or were terminated, 262 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
318 of 926 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
83 of the studies in Carcinoma, Hepatocellular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03654053Phase 3VA Office of Research and DevelopmentMulti-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT01918683Abramson Cancer Center at Penn MedicineTACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | 2026-12 |
| NCT04410302University of California, DavisPatient-Derived Xenografts to Reduce Cancer Health Disparities | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label, uncontrolled, Phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
The goal of this clinical trial is to investigate if ABX196 in combination with nivolumab can benefit adult patients with hepatocellular carcinoma.
The criteria were revised on the registry on Sep 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalation: ABX196 at 0.1, 0.2, or 0.4 µg i.m. was administered after completion of nivolumab infusion on Day 1 of every other 28-day treatment cycle (i.e., every 8 weeks). Nivolumab 240 mg i.v. was administered on Days 1 and 15 of each 28-day cycle.
Drug: ABX196
ABX196 is a synthetic agonist of invariant Natural Killer T (iNKT) cells
Also known as: Obefazimod
This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.
Incidence and Severity of Adverse Events (AEs)
Incidence and severity of adverse events evaluated according to CTC-AE
Time frame: From first day of treatment (randomization visit) up to 64 weeks of treatment + up to 30 days of safety follow-up (total: up to 478 days)
Objective Response Rate (ORR)
Defined as the proportion of subjects with a best response of complete response or partial response according to RECIST V1.1
Time frame: From first dose of treatment (randomization visit) up to 64 weeks treatment
Progression Free Survival (PFS)
Defined as time from first dose of ABX196 to disease progression or death
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks
Time to Progression (TTP)
Defined as time from first dose of study ABXX196 to disease progression or death
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 64 weeks
Change in Alpha Fetoprotein Serum
Change in alpha fetoprotein serum concentrations
Time frame: From first dose of treatment (randomization visit) up to 64 weeks treatment
| Milestone | ABX196 0.1 µg i.m. | ABX196 0.2 µg i.m. | ABX196 0.4 µg i.m. |
|---|---|---|---|
| Started | 4 | 3 | 3 |
| Completed | 2 | 1 | 2 |
| Not completed | 2 | 2 | 1 |
Incidence and severity of adverse events evaluated according to CTC-AE
| Participants | ABX196 0.1 µg i.m. | ABX196 0.2 µg i.m. | ABX196 0.4 µg i.m. |
|---|---|---|---|
| Any TEAE, n (%) | 4 | 2 | 3 |
| Any Serious TEAE, n (%) | 1 | 0 | 0 |
| Any ABX196-related TEAE, n (%) | 2 | 2 | 0 |
| Any nivolumab-related TEAE, n (%) | 3 | 2 | 0 |
| Any serious ABX196-related TEAE, n (%) | 0 | 0 | 0 |
| Any serious nivolumab-related TEAE, n (%) | 0 | 0 | 0 |
Defined as the proportion of subjects with a best response of complete response or partial response according to RECIST V1.1
| Participants | ABX196 0.1 µg i.m. | ABX196 0.2 µg i.m. | ABX196 0.4 µg i.m. |
|---|---|---|---|
| Objective Response Rate (ORR) | 1 | 0 | 0 |
| Complete Response Rate (CR) | 0 | 0 | 0 |
| Partial Response Rate (PR) | 1 | 0 | 0 |
Defined as time from first dose of ABX196 to disease progression or death
| Days | ABX196 0.1 µg i.m. | ABX196 0.2 µg i.m. | ABX196 0.4 µg i.m. |
|---|---|---|---|
| Progression Free Survival (PFS) | 340.5 (44 to NA) | 56 (53 to NA) | 56 (56 to NA) |
Defined as time from first dose of study ABXX196 to disease progression or death
| Days | ABX196 0.1 µg i.m. | ABX196 0.2 µg i.m. | ABX196 0.4 µg i.m. |
|---|---|---|---|
| Time to Progression (TTP) | 340.5 (44 to NA) | 56 (53 to NA) | 56 (56 to NA) |
Change in alpha fetoprotein serum concentrations
| Participants | ABX196 0.1 µg i.m. | ABX196 0.2 µg i.m. | ABX196 0.4 µg i.m. |
|---|---|---|---|
| Cycle 1 Day 1 AFP Responders, n (%) | 0 | — | 0 |
| Cycle 1 Day 15 AFP Responders, n (%) | 0 | — | — |
| Cycle 2 Day 1 AFP Responders, n (%) | 0 | — | 0 |
| Cycle 3 Day 1 AFP Responders, n (%) | 1 | — | 0 |
| Cycle 4 Day 1 AFP Responders, n (%) | 1 | — | 0 |
| Cycle 5 Day 1 AFP Responders, n (%) | 1 | — | 0 |
| Cycle 6 Day 1 AFP Responders, n (%) | 1 | — | 0 |
| Cycle 7 Day 1 AFP Responders, n (%) | 1 | — | 0 |
| Cycle 8 Day 1 AFP Responders, n (%) | 1 | — | — |
| Cycle 9 Day 1 AFP Responders, n (%) | 1 | — | — |
| Cycle 10 Day 1 AFP Responders, n (%) | 1 | — | — |
| Cycle 11 Day 1 AFP Responders, n (%) | 1 | — | — |
| Cycle 12 Day 1 AFP Responders, n (%) | 1 | — | — |
| Cycle 13 Day 1 AFP Responders, n (%) | 1 | — | — |
| Cycle 14 Day 1 AFP Responders, n (%) | 1 | — | — |
| Cycle 15 Day 1 AFP Responders, n (%) | 1 | — | — |
| Cycle 16 Day 1 AFP Responders, n (%) | 0 | — | — |
| Termination AFP Responders, n (%) | 1 | — | 0 |
Collected over From first day of treatment (randomization visit) up to 64 weeks of treatment + up to 30 days of safety follow-up (total: up to 478 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX196 0.1 µg | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| ABX196 0.2 µg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| ABX196 0.4 µg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | ABX196 0.1 µg | ABX196 0.2 µg | ABX196 0.4 µg |
|---|---|---|---|
| CellulitisInfections and infestations | 1/4 | — | — |
| Event | ABX196 0.1 µg | ABX196 0.2 µg | ABX196 0.4 µg |
|---|---|---|---|
| FatigueGeneral disorders | 2/4 | 2/3 | 0/3 |
| Platelet count decreaseInvestigations | 2/4 | 2/3 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 0/3 | 1/3 |
| Abdominal pain lowerGastrointestinal disorders | 2/4 | 0/3 | 0/3 |
| Back painMusculoskeletal and connective tissue disorders | 2/4 | 0/3 | 0/3 |
| HypertensionVascular disorders | 2/4 | 0/3 | 0/3 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/4 | 0/3 | 0/3 |
| Abdominal painGastrointestinal disorders | 1/4 | 1/3 | 0/3 |
| VomitingGastrointestinal disorders | 0/4 | 1/3 | 0/3 |
| Injection site painGeneral disorders | 0/4 | 1/3 | 0/3 |
| Age, Categorical(Participants) | ABX196 0.1 µg i.m | ABX196 0.2 µg i.m | ABX196 0.4 µg i.m | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 1 | 4 |
| >=65 years | 3 | 1 | 2 | 6 |
| Age, Continuous(Years) | ABX196 0.1 µg i.m | ABX196 0.2 µg i.m | ABX196 0.4 µg i.m | Total |
|---|---|---|---|---|
| Mean | 65.8 (49 to 76) | 60.3 (53 to 67) | 64 (60 to 67) | 63.6 (49 to 76) |
| Sex: Female, Male(Participants) | ABX196 0.1 µg i.m | ABX196 0.2 µg i.m | ABX196 0.4 µg i.m | Total |
|---|---|---|---|---|
| Female | 0 | 1 | 1 | 2 |
| Male | 4 | 2 | 2 | 8 |
| Race/Ethnicity, Customized(Participants) | ABX196 0.1 µg i.m | ABX196 0.2 µg i.m | ABX196 0.4 µg i.m | Total |
|---|---|---|---|---|
| Race — Asian | 1 | 1 | 1 | 3 |
| Race — Black or African American | 0 | 1 | 0 | 1 |
| Race — White | 3 | 1 | 2 | 6 |
| Region of Enrollment(Participants) | ABX196 0.1 µg i.m | ABX196 0.2 µg i.m | ABX196 0.4 µg i.m | Total |
|---|---|---|---|---|
| United States | 4 | 3 | 3 | 10 |
| Hepatocellular Carcinoma(Participants) | ABX196 0.1 µg i.m | ABX196 0.2 µg i.m | ABX196 0.4 µg i.m | Total |
|---|---|---|---|---|
| Count of participants | 4 | 3 | 3 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Apr 2022, 25 months.
Results were first posted in Sep 2026, 4 years 5 months after primary completion.
Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 25 months is below that.
Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Aug 2019 → Feb 2020, primary completion Jun 2021 → Apr 2022 and completion Jun 2023 → Apr 2022.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.